Statistik Asas
| CIK | 1479681 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nutex Health Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| September 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2025 (September 2, 2025) NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporat |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2025 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 21, 2025 |
NUTEX HEALTH PROVIDES FINANCIAL REPORTING UPDATE Exhibit 99.1 NUTEX HEALTH PROVIDES FINANCIAL REPORTING UPDATE HOUSTON, TX − (PRNewswire) – AUGUST 20, 2025 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments in 11 states and primary care-centric, risk-bearing physician networks, today discl |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-41346 CUSIP Number: 67079U306 (Check one): o Form 10-K o Form 20-F o Form 11-K x Form 10-Q o Form 10-D o Form N-CEN o Form N-CSR For Period Ended: June 30, 2025 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Trans |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 14, 2025 |
NUTEX HEALTH PROVIDES PRELIMINARY SECOND QUARTER FINANCIAL RESULTS, ANNOUNCES DELAY IN FILING ITS 2025 SECOND QUARTER FINANCIAL STATEMENTS AND ANNOUNCES A STOCK REPURCHASE PROGRAM OF UP TO $25 MILLION HOUSTON, TX − (PRNewswire) – AUGUST 14, 2025 – Nutex Health Inc. |
|
| July 16, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 11, 2025 (July 8, 2025) NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Com |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definiti |
|
| June 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definiti |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definiti |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒Definiti |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definiti |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐Definiti |
|
| May 21, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2025 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 21, 2025 | ||
| May 13, 2025 |
NUTEX HEALTH reports FIRST quarter 2025 financial results NUTEX HEALTH reports FIRST quarter 2025 financial results ● Total revenue of $211. |
|
| May 13, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 13, 2025 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 2, 2025 |
NUTEX HEALTH INC. Up to 78,424 Shares of Common Stock Issuable Upon Exercise of Warrants Filed pursuant to Rule 424(b)(3) File No. 333-286554 PROSPECTUS NUTEX HEALTH INC. Up to 78,424 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus relates to the resale from time to time by the selling securityholders identified in this prospectus (the “Selling Securityholders”) of up to 78,424 shares of our common stock, par value $0.001 per share (the “Common Stock”), issua |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi |
|
| April 29, 2025 |
NUTEX HEALTH INC. 6030 S. Rice, Suite C Houston, TX 77081 Correspondence NUTEX HEALTH INC. 6030 S. Rice, Suite C Houston, TX 77081 VIA EDGAR April 29, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3561 Re: Nutex Health Inc. Registration Statement on Form S-3 File No. 333-286554 Ladies and Gentlemen: On behalf of Nutex Health Inc., and pursuant to Rule 461 promulgated under |
|
| April 25, 2025 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2025 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 25, 2025 | ||
| April 23, 2025 |
As filed with the Securities and Exchange Commission on April 22, 2025 As filed with the Securities and Exchange Commission on April 22, 2025 Registration No. |
|
| April 15, 2025 |
Managing Dealer Agreement, by and between the Company and Emerson Equity LLC, dated October 7, 2019 Exhibit 4.5 MANAGING DEALER AGREEMENT (the “Agreement”) October 7, 2019 Dominic Baldini Emerson Equity UC 155 Bovet Road, Suite 725 San Mateo, CA 94402 Dear Mr. Baldini, Clinigence Holdings, Inc., a Delaware corporation (the “Company”) proposes to raise $1,000,000 (subject to increase up to $2,000,000 by the Company in its sole discretion) through the sale of investment units (the “Units”), each c |
|
| April 15, 2025 |
Exhibit 4.10 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Nutex Health Inc. (the “Company” or “we”) is based upon the Company’s amended and restated certificate of incorporation, as amended to date, and the Company’s second amended and restated bylaws an |
|
| April 15, 2025 |
Exhibit 4.7 WARRANT THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICA |
|
| April 15, 2025 |
As filed with the Securities and Exchange Commission on April 15, 2025 As filed with the Securities and Exchange Commission on April 15, 2025 Registration No. |
|
| April 15, 2025 |
Managing Dealer Agreement, by and between the Company and Emerson Equity LLC, dated June 15, 2020 Exhibit 4.4 MANAGING DEALER AGREEMENT (the “Agreement”) June 15, 2020 Dominic Baldini Emerson Equity LLC 155 Bovet Road, Suite 725 San Mateo, CA 94402 Dear Mr. Baldini, Accountable Healthcare America, Inc., a Delaware corporation (the “Company”) proposes to raise a maximum of $5,000,000 through the sale of up to 100 investment units (the “Units”) priced at $2.00 per unit, with each Unit consisting |
|
| April 15, 2025 |
Placement Agent Agreement, by and between the Company and Emerson Equity LLC, dated July 27, 2023 Exhibit 4.3 PLACEMENT AGENT AGREEMENT (the “Agreement”) July 2, 2023 Dominic Baldini Emerson Equity LLC 155 Bovet Road, Suite 725 San Mateo, CA 94402 Dear Mr. Baldini, Nutex Health Inc., a Delaware corporation (“Nutex Health” or the “Company”), proposes to raise a maximum of $15,000,000 through the sale of investment units of the Company (the “Units”), with each Unit consisting of one share of com |
|
| April 15, 2025 |
Amendment to Warrant Agreement dated March 26, 2024 Exhibit 4.9 AMENDMENT TO WARRANT AGREEMENT This AMENDMENT TO WARRANT AGREEMENT (the “Warrant Amendment”) is made as of March 26, 2024, by and between Nutex Health Inc., a Delaware corporation (the “Company”), and Michael DiMeo (the “Holder”). WHEREAS, the Company and the Holder are parties to that certain Stock Purchase Warrant dated December 31, 2023 (the “Original Warrant”); and WHEREAS, the Com |
|
| April 15, 2025 |
Form of 2019 Stock Purchase Warrant Exhibit 4.2 WARRANT THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICA |
|
| April 15, 2025 |
Exhibit 4.6 WARRANT THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICA |
|
| April 15, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nutex Health Inc. |
|
| April 15, 2025 |
Exhibit 4.8 WARRANT THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICA |
|
| March 31, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| March 31, 2025 |
Nutex Health Inc. Compensation Recovery Policy EXHIBIT 97.1 Nutex Health Inc. Compensation Recovery Policy 1.Introduction The Board of Directors (the “Board”) of Nutex Health Inc., a corporation organized under the laws of Delaware (the “Company”), has adopted this policy (this “Policy”), which provides for the recovery of erroneously awarded Incentive-based Compensation (as defined below) from current and former executive officers in the even |
|
| March 31, 2025 |
NUTEX HEALTH reports FOURTH quarter and FULL year 2024 financial results NUTEX HEALTH reports FOURTH quarter and FULL year 2024 financial results Full year 2024 highlights: ● Total revenue of $479. |
|
| March 31, 2025 |
NUTEX HEALTH INC. SECURITIES TRADING POLICY I.Introduction Federal and state securities laws make it illegal for anyone to trade in a company’s securities while in possession of material, nonpublic information relating to that company. This conduct is referred to as “insider trading” and may result in civil or criminal penalties. The purpose of this Securities Trading Policy (this “Policy”) is to |
|
| March 31, 2025 |
Exhibit 21.1 NUTEX HEALTH INC. SUBSIDIARIES Company Jurisdiction of Organization Nutex Health Holdco LLC Delaware Tyvan LLC (100% Owned Subsidiary of Nutex Health Holdco LLC) Texas Nutex Health LLC (100% Owned Subsidiary of Nutex Health Holdco LLC) Texas AHP Health Management Services, Inc. Delaware Accountable Healthcare America, Inc. Delaware South Florida Physicians IPA, Inc. (100% Owned Subs |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41346 NUTEX HEAL |
|
| February 6, 2025 |
Nutex Health Issues No Surprises Act (NSA) Arbitration Update Exhibit 99.1 Nutex Health Issues No Surprises Act (NSA) Arbitration Update HOUSTON, February 5, 2025 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro-hospitals in 11 states and primary care-centric, risk-bearing physician networks, today provided an update regarding its strategic part |
|
| February 6, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2025 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 14, 2024 |
NUTX / Nutex Health Inc. / HIGHBRIDGE CAPITAL MANAGEMENT LLC - NUTEX HEALTH, INC. Passive Investment SC 13G 1 p24-3244sc13g.htm NUTEX HEALTH, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nutex Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67079U306 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the approp |
|
| November 7, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 7, 2024 |
NUTEX HEALTH reports third quarter and year to date September 30, 2024 financial results NUTEX HEALTH reports third quarter and year to date September 30, 2024 financial results ● Total revenue of $222. |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 8, 2024 |
NUTEX HEALTH reports SECOND quarter and Six months ended June 30, 2024 financial results NUTEX HEALTH reports SECOND quarter and Six months ended June 30, 2024 financial results ● Total revenue of $143. |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 8, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 24, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 5, 2024 |
Amendment No. 2 to Second Amended and Restated Certificate of Incorporation Exhibit 3.1 AMENDMENT NO. 2 TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUTEX HEALTH INC. Nutex Health Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”) does hereby certify that: 1. The name of this Corporation is Nutex Health Inc. and this Corporation was originally incorporated pursuant to the General Corp |
|
| July 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 1, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 26, 2024 |
As filed with the Securities and Exchange Commission on June 26, 2024 As filed with the Securities and Exchange Commission on June 26, 2024 Registration No. |
|
| June 26, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLE FORM S-8 (Form Type) NUTEX HEALTH INC. |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2024 (June 14, 2024) NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Co |
|
| May 24, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 9, 2024 |
NUTEX HEALTH reports FIRST quarter 2024 financial results NUTEX HEALTH reports FIRST quarter 2024 financial results ● Total revenue of $67.5 million for fIRST qUARTER 2024 vs $56.3 Million in 2023, an increase of 20% ● HOSPITAL DIVISION VISITS OF 40,068 FOR THE FIRST QUARTER 2024 VS VISITS OF 33,085 IN 2023, An increase of 21.1% ● hospital division operating income of $10.5 million for FIRST QUARTER 2024 VS $4.8 million in 2023, an increase of 119% ● Net |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 6, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0 |
|
| April 26, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 11, 2024 |
Amendment to Second Amended and Restated Certificate of Incorporation EXHIBIT 3.1 AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NUTEX HEALTH INC. Nutex Health Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”) does hereby certify that: 1. The name of this Corporation is Nutex Health Inc. and this Corporation was originally incorporated pursuant to the General Corporatio |
|
| April 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 9, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 8, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 29, 2024 |
Form of 8% Convertible Promissory Note due October 31, 2025 Exhibit 4.12 FORM OF CONVERTIBLE PROMISSORY NOTE THIS NOTE HAS NOT BEEN REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION OF THE UNITED STATES AND MAY NOT BE SOLD OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN APPLICABLE EXEMPT |
|
| March 29, 2024 |
EXHIBIT 10.31 Amendment to Employment Agreement THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of January 31, 2024 (the “Amendment Effective Date”), by and between Nutex Health Inc., a Delaware corporation (the “Company”), and Michael Chang (the “Employee” and, together with the Company, the “Parties”). Whereas, the Company and Executive entered int |
|
| March 29, 2024 |
Form of Restricted Unit Award Agreement EXHIBIT 10.27 NUTEX HEALTH INC. AMENDED AND RESTATED NUTEX HEALTH INC. 2022 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE Nutex Health Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Restricted Stock Units (the “RSUs”) described in this Restricted Stock Unit Grant Notice (this “Grant Notice”), subject to the terms and conditi |
|
| March 29, 2024 |
Employment Agreement between Nutex Health Inc. and Michael Chang dated as of September 9, 2022 EXHIBIT 10.30 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of September 9, 2022, by and between Nutex Health, Inc., a Delaware corporation (the “Company”), and Michael Chang, M.D., (the “Employee”), each individually a “party” and collectively the “Parties,” to become effective as of the date hereof (the “Effective Date”). For good and valuable con |
|
| March 29, 2024 |
EXHIBIT 10.20 AMENDMENT TO EMPLOYMENT AGREEMENT This AMENDMENT TO EMPLOYMENT AGREEMENT (this "Amendment"), dated as of July 1, 2021, to the Employment Agreement dated as of October 29, 2019 (the "Employment Agreement"), by and between Clinigence Holdings, Inc., a Delaware corporation (the "Company"), and Elisa Luqman ("Employee"). WHEREAS, the Company and Employee have previously entered into the |
|
| March 29, 2024 |
Form of Notice of Grant and Stock Option Agreement EXHIBIT 10.25 NUTEX HEALTH INC. [PLAN NAME] NOTICE OF GRANT OF STOCK OPTION AND STOCK OPTION AGREEMENT You have been granted an option to purchase Common Stock of the Corporation, subject to the terms and conditions of the Plan and this Agreement, as follows: Optionee: Grant Date: Number of Shares: Expiration Date: Exercise Price Per Share:$ Type of Option:Incentive Stock Option / Nonstatutory Sto |
|
| March 29, 2024 |
Form of Stock Purchase Warrant expiring December 31, 2029 FORM OF WARRANT THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (II) TO THE EXTENT APPLICABLE, RULE 144 UNDER THE ACT (OR ANY SIMILAR RULE UNDER THE ACT RELATING TO THE DISPOSITION OF SECURITIES), OR (III) AN OPINION OF COUNSEL, IF SUCH OPINION SHALL BE REASONABLY SATISFACTORY TO COUNSEL TO THE ISSUER, THAT AN EXEMPTION FROM REGISTRATION UNDER THE ACT AND APPLICABLE STATE LAW IS AVAILABLE. |
|
| March 29, 2024 |
Nutex Health Inc. Compensation Recovery Policy EXHIBIT 97.1 Nutex Health Inc. Compensation Recovery Policy 1.Introduction The Board of Directors (the “Board”) of Nutex Health Inc., a corporation organized under the laws of Delaware (the “Company”), has adopted this policy (this “Policy”), which provides for the recovery of erroneously awarded Incentive-based Compensation (as defined below) from current and former executive officers in the even |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41346 NUTEX HEAL |
|
| March 29, 2024 |
EXHIBIT 10.19 Amendment to Employment Agreement THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered into effective as of February 22, 2021 (the “Amendment Effective Date”), by and between Clinigence Holdings, Inc., a Delaware corporation (the “Company”), and Elisa Luqman (the “Employee” and, together with the Company, the “Parties”). Whereas, the Company and Executive ent |
|
| March 29, 2024 |
Termination of Pre-Paid Advance Agreement dated February 8, 2024 EXHIBIT 10.28 February 8, 2024 YA II PN, Ltd. 1012 Springfield Avenue Mountainside, NJ 07092 Attention: Michael Rosselli Email:***** Attention: David Fine, Esq. Email: ***** Subject: Termination of Pre-Paid Advance Agreement Dear Michael, As previously discussed, I am writing to formally notify you of Nutex Health Inc.’s intention to terminate our Pre-Paid Advance Agreement (the “Agreement”) dated |
|
| March 29, 2024 |
Form of Restricted Stock Award Agreement EXHIBIT 10.26 NUTEX HEALTH, INC. 2022 EQUITY INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT NOTIFICATION OF AWARD AND TERMS AND CONDITIONS OF AWARD Name of Grantee: Grant Date: Number of Shares: Restricted Period(s)See Paragraph 5 This Restricted Stock Award Agreement (the “Agreement”) contains the terms and conditions of the restricted stock award granted to you by Nutex Health Inc., a Delaware |
|
| March 29, 2024 |
EXHIBIT 10.21 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This THIRD AMENDMENT TO EMPLOYMENT AGREEMENT (this "Amendment"), dated as of August 15, 2021, to the Employment Agreement dated as of October 29, 2019, as Amended on February 22, 2021 and July 1, 2021 (collectively the "Employment Agreement"), by and between Clinigence Holdings, Inc., a Delaware corporation (the "Company"), and Elisa Luqman ("E |
|
| March 29, 2024 |
Exhibit 21.1 NUTEX HEALTH INC. SUBSIDIARIES Company Jurisdiction of Organization Nutex Health Holdco LLC Delaware Tyvan LLC Texas Nutex Health LLC Texas Clinigence Health, Inc. Delaware AHP Health Management Services, Inc. Delaware Procare Health Inc. California Accountable Healthcare America, Inc. Delaware South Florida Physicians IPA, Inc. (100% Owned Subsidiary of Accountable Healthcare Ameri |
|
| March 29, 2024 |
Exhibit 10.18 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of October 29, 2019, by and between Clinigence Holdings, Inc., a Delaware corporation (the “Company”), and Elisa Luqman (the “Employee” and together with the Company referred to as the “Parties”) to become effective as of the date hereof (the “Effective Date”). For good and valuable consider |
|
| March 29, 2024 |
EXHIBIT 10.22 AMENDMENT #4 TO EMPLOYMENT AGREEMENT This AMENDMENT #4 TO EMPLOYMENT AGREEMENT (this "Amendment"), dated as of June 14, 2022, to the Employment Agreement dated as of October 29, 2019, and as Amended on August 15, 2021, February 22, 2021, and July 1, 2021 (collectively the "Employment Agreement") (the "Employment Agreement"), by and between Nutex Health Inc. (formerly Clinigence Holdi |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| March 28, 2024 |
NUTEX HEALTH reports fourth quarter and Full YEAR 2023 financial results NUTEX HEALTH reports fourth quarter and Full YEAR 2023 financial results ● Total revenue of $247. |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-41346 CUSIP Number: 67079U 108 (Check one): X Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-CEN Form N-CSR For Period Ended: December 31, 2023 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on F |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 29, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 15, 2024 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 15, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 9, 2024 |
Exhibit 10.1 ADDENDUM TO EMPLOYMENT AGREEMENT THIS ADDENDUM TO EMPLOYMENT AGREEMENT (this “Addendum”) made and entered into on February 8, 2024, by and between Nutex Health, Inc., a Delaware corporation (the “Company”), and Thomas T. Vo (the “Executive” and together with the Company referred to as the “Parties”) modifies the existing Employment Agreement between the Parties dated April 1, 2022 (th |
|
| January 24, 2024 |
Form of Securities Purchase Agreement dated as of January 22, 2024. Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 22, 2024, between Nutex Health Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditio |
|
| January 24, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 22, 2024 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| January 24, 2024 |
Placement Agency Agreement between Maxim Group LLC and the Company dated January 22, 2024. Exhibit 10.1 PLACEMENT AGENCY AGREEMENT January 22, 2024 Maxim Group LLC 300 Park Avenue, 16th Floor New York, New York 10022 Ladies and Gentlemen: This agreement (the “Agreement”) constitutes the agreement between Maxim Group LLC (the “Placement Agent”) and Nutex Health, Inc., a Delaware corporation (the “Company”), pursuant to which the Placement Agent shall serve as the exclusive plac |
|
| January 24, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-270886 Prospectus Supplement (to Prospectus dated April 7, 2023) 66,666,666 Shares of Common Stock Warrants to Purchase 66,666,666 Shares of Common Stock 66,666,666 Shares of Common Stock Underlying the Warrants We are offering to certain investors pursuant to this prospectus supplement and the accompanying prospectus 66,666 |
|
| January 24, 2024 |
Exhibit 99.1 RISK FACTORS As of the date of this Current Report, the Company updates and supplements the risk factors disclosed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed with the SEC on March 3, 2023, as supplemented and updated by the risk factors disclosed in the Company’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 30, 2023, Jun |
|
| January 24, 2024 |
Form of Common Stock Purchase Warrant Exhibit 4.1 COMMON STOCK PURCHASE WARRANT NUTEX HEALTH INC. Warrant Shares: [●] CUSIP: [●] ISIN: [●] Issue Date: [●], 2024 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date (the “In |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2024 NUTEX HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| January 11, 2024 |
Exhibit 99.1 S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L C O N F I D E N T I A L 2 General The information contained in this Investor Presentation (“Presentation”) has been prepared by Nutex Health Inc. (“NUTX” or the “Company”) for investors, solely for informational purposes. The Presentation has been prepared to assist |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 21, 2023 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 9, 2023 |
Employment Agreement, dated as of August 28, 2023, between the Company and Joshua DeTillio. Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the 28th day of August, 2023, by and between Nutex Health, Inc., a Delaware corporation (the “Company”), and Joshua DeTillio, (the “Employee”), each individually a “Party” and collectively the “Parties”. For good and valuable consideration, the receipt and sufficiency of which are hereby a |
|
| November 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 9, 2023 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 9, 2023 |
NUTEX HEALTH reports THIRd quarter 2023 financial results NUTEX HEALTH reports THIRd quarter 2023 financial results ● NET revenue of $62.7 million ● NET CASH FROM OPERATING ACTIVITIES OF $2.0 MILLION ● Company expects to open FIVE NEW MICRO-HOPITALS IN 2024 HOUSTON, TX − (PRNewswire) – November 9, 2023 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised |
|
| September 26, 2023 |
NUTX / Nutex Health Inc / Premier Macy Management Holdings, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* NUTEX HEALTH INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 67079U 108 (CUSIP Number) Premier MACY Management Holdings, LLC Attn: Matthew Stephen Young 2819 Cypress Dr. Texarkana, TX 75503 (713) 226-1200 W |
|
| September 5, 2023 |
NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF JOSHUA DETILLIO AS ITS NEW CHIEF OPERATING OFFICER Exhibit 99.1 NUTEX HEALTH ANNOUNCES THE APPOINTMENT OF JOSHUA DETILLIO AS ITS NEW CHIEF OPERATING OFFICER HOUSTON, TX – September 5, 2023 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 28, 2023 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| September 5, 2023 |
Employment Agreement, dated as of August 28, 2023, between the Company and Joshua DeTillio. Exhibit 10.01 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of the day of , 2023, by and between Nutex Health, Inc., a Delaware corporation (the “Company”), and Joshua DeTillio, (the “Employee”), each individually a “Party” and collectively the “Parties”. For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledge |
|
| August 23, 2023 |
Exhibit 99.1 NUTEX HEALTH ANNOUNCES THE ACQUISITION OF POPULATION HEALTH ASSOCIATES AND MANAGED CARE INSURANCE CONSULTANTS ACQUISITION EXPANDS COMPANY’S PRESENCE IN FLORIDA AND ADDS APPROXIMATELY 112 PRIMARY CARE PHYSICIANS AND 4400 MANAGED CARE PATIENTS TO THE NUTEX PLATFORM HOUSTON, TX − (PRNewswire) – August 22, 2023 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physic |
|
| August 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2023 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 9, 2023 |
NUTEX HEALTH reports Second quarter 2023 financial results NUTEX HEALTH reports Second quarter 2023 financial results ● NET revenue of $58.9 million ● Company expects to open 1-2 more hospitals in 2023 and another 14 by end of 2025 HOUSTON, TX − (PRNewswire) – AUGUST 9, 2023 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro- |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2023 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00 |
|
| July 25, 2023 |
As filed with the Securities and Exchange Commission on July 24, 2023 As filed with the Securities and Exchange Commission on July 24, 2023 Registration No. |
|
| July 25, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) NUTEX HEALTH INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1)(2) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par |
|
| July 7, 2023 |
NUTX / Nutex Health Inc / Premier Macy Management Holdings, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NUTEX HEALTH INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 67079U 108 (CUSIP Number) Premier MACY Management Holdings, LLC Attn: Matthew Stephen Young 2819 Cypress Dr. Texarkana, TX 75503 (713) 226-1200 With |
|
| July 5, 2023 |
Second Amended and Restated Certificate of Incorporation Exhibit 3.1 Delaware Page 1 The First State I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF “NUTEX HEALTH INC.”, FILED IN THIS OFFICE ON THE THIRTIETH DAY OF JUNE, A.D. 2023, AT 5 O`CLOCK P.M. 3211383 8100 SR# 20232906685 Authentication: 203672509 Date: 07-03-23 You may verify this certific |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 29, 2023 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| July 5, 2023 |
Nutex Health Inc. 2023 Employee Stock Purchase Plan NUTEX HEALTH INC. 2023 EMPLOYEE STOCK PURCHASE PLAN 1.Purpose and History. The purpose of the Nutex Health Inc. 2023 Employee Stock Purchase Plan (the “Plan”) is to advance the interests of Nutex Health Inc., a Delaware corporation (the “Company”), and its shareholders by providing Eligible Employees (as defined below) of the Company and its Designated Subsidiaries (as defined below) with an oppor |
|
| June 26, 2023 |
Nutex Health Inc. 90,226,077 Shares of Common Stock Offered by the Selling Stockholders Filed pursuant to Rule 424(b)(3) File No. 333-267686 PROSPECTUS Nutex Health Inc. 90,226,077 Shares of Common Stock Offered by the Selling Stockholders This prospectus relates to the resale of an aggregate of 90,226,077 shares of common stock, par value $0.001 per share (“Common Stock”), held by former holders of member interests of Nutex Health Holdco LLC, now a wholly owned subsidiary of Nutex H |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2023 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 19, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 15, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0 |
|
| May 15, 2023 |
NUTEX HEALTH INC. CONDENSED CONSOLIDATED BALANCE SHEETS NUTEX HEALTH reports FIRST quarter 2023 financial results ● NET revenue of $56.3 million ● Net cash from operating activities of $1.1 million ● Company expects to open 4-5 more hospitals in 2023 and another 14 by end of 2025 HOUSTON, TX − (PRNewswire) – MAY 15, 2023 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare deliv |
|
| May 15, 2023 |
Employment Agreement by and between the Company and Pamela Montgomery dated August 8, 2022. Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into as of August 8, 2022, by and between Nutex Health, Inc., a Delaware corporation (the "Company"), and Pamela Montgomery, (the "Employee" and together with the Company referred to as the "Parties") to become effective as of the date hereof (the "Effective Date"). For good and valuable consideratio |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2023 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Perio |
|
| May 9, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| May 2, 2023 |
Exhibit 99.1 S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L C O N F I D E N T I A L 2 General The information contained in this Investor Presentation (“Presentation”) has been prepared by Nutex Health Inc. (“NUTX” or the “Company”) for investors, solely for informational purposes. The Presentation has been prepared to assist |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2023 NUTEX HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 12, 2023 |
Nutex Health Inc. Common Stock TABLE OF CONTENTS Filed pursuant to Rule 424(b)(5) Registration No. 333-270886 PROSPECTUS SUPPLEMENT (To Prospectus Dated April 7, 2023) $25,000,000 Nutex Health Inc. Common Stock We are offering $25,000,000 of our common stock, par value $0.001 per share (our “Common Stock”), by this prospectus supplement and the accompanying prospectus, directly to YA II PN, Ltd., a Cayman Islands exempt limi |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2023 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 12, 2023 |
Exhibit 10.1 PRE-PAID ADVANCE AGREEMENT THIS PRE-PAID ADVANCE AGREEMENT (this “Agreement”) dated as of April 11, 2023 is made by and between YA II PN, LTD., a Cayman Islands exempt limited partnership (the “Investor”), and NUTEX HEALTH INC., a company incorporated under the laws of the State of Delaware (the “Company”). WHEREAS, the parties desire that, upon the terms and subject to the conditions |
|
| April 12, 2023 |
Exhibit 99.1 NUTEX HEALTH announces that it has entered into a $100 million pre-paid advance agreement with yorkville advisors global l.p. HOUSTON, TX − (PRNewswire) – APRIL 11, 2023 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 20 state-of-the-art micro hospitals in 8 states and primary |
|
| April 12, 2023 |
Lincoln Park Capital Fund, LLC Exhibit 99.2 Lincoln Park Capital Fund, LLC April 11, 2023 Ladies and Gentlemen: Reference is made to the Purchase Agreement (the “Lincoln Park Equity Line”), dated effective as of November 14, 2022, by and between Nutex Health Inc., a Delaware corporation (the “Company”), and Lincoln Park Capital Fund, LLC, an Illinois limited liability company (“LPCF”). Capitalized terms used herein and not othe |
|
| April 7, 2023 |
VIA EDGAR April 7, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 7, 2023 |
TABLE OF CONTENTS Filed pursuant to Rule 424(b)(3) File No. 333-270886 PROSPECTUS $300,000,000 Nutex Health Inc. Common Stock Senior Debt Securities Subordinated Debt Securities Warrants Rights From time to time, we may offer and sell any combination of the securities described in this prospectus in one or more offerings. The securities we may offer may be convertible into or exercisable or exc |
|
| April 7, 2023 |
VIA EDGAR April 7, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41346 NUTEX HE |
|
| April 5, 2023 |
NUTEX HEALTH announces change to its board of directors Exhibit 99.1 NUTEX HEALTH announces change to its board of directors HOUSTON, TX − (PRNewswire) – APRIL 5, 2023 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 20 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced the depa |
|
| April 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2023 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| March 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) NUTEX HEALTH INC. |
|
| March 28, 2023 |
Form of Senior Indenture between the Registrant and one or more trustees to be named Exhibit 4.3 NUTEX HEALTH INC. to [TRUSTEE] Trustee INDENTURE Dated as of [ ] SENIOR DEBT SECURITIES NUTEX HEALTH INC. Certain Sections of this Indenture relating to Sections 310 through 318, inclusive, of the Trust Indenture Act of 1939 Trust Indenture Act Section Indenture Section Section 3.10(a)(1) 6.09 (a)(2) 6.09 (a)(3) Not Applicable (a)(4) Not Applicable (b) 6.08 Section 3.11(a) 6. |
|
| March 28, 2023 |
Form of Subordinated Debt Indenture between the Registrant and one or more trustees to be named Exhibit 4.4 NUTEX HEALTH INC. to [TRUSTEE], Trustee INDENTURE Dated as of [ ] SUBORDINATED DEBT SECURITIES NUTEX HEALTH INC. Certain Sections of this Indenture relating to Sections 310 through 318, inclusive, of the Trust Indenture Act of 1939 Trust Indenture Act Section Indenture Section Section 3.10(a)(1) 6.09 (a)(2) 6.09 (a)(3) Not Applicable (a)(4) Not Applicable (b) 6.08 Section 3.11 |
|
| March 28, 2023 |
As filed with the Securities and Exchange Commission on March 27, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 27, 2023 Registration No. |
|
| March 10, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 10, 2023 Table of Contents As filed with the U.S. Securities and Exchange Commission on March 10, 2023 Registration No. 333-267686 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 11-3363609 (State or othe |
|
| March 3, 2023 |
Exhibit 21.1 NUTEX HEALTH INC. SUBSIDIARIES Company Jurisdiction of Organization Nutex Health Holdco LLC Delaware Tyvan LLC Texas Nutex Health LLC Texas Clinigence Health, Inc. Delaware AHP Health Management Services, Inc. Delaware Procare Health Inc. California Accountable Healthcare America, Inc. Delaware South Florida Physicians IPA, Inc. (100% Owned Subsidiary of Accountable Healthcare Ameri |
|
| March 3, 2023 |
Form of Restricted Stock Award Rescission Agreement Exhibit 10.14 NUTEX HEALTH INC. RESTRICTED STOCK AWARD RESCISSION AGREEMENT This Restricted Stock Award Rescission Agreement (this “Rescission Agreement”) is entered into as of December [•], 2022 (the “Rescission Date”), by and between [NAME] (the “Director”) and Nutex Health Inc. (the “Company”), (each, a “Party” and collectively, the “Parties”). RECITALS WHEREAS, the Director and the Company are |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-41346 NUTEX HEAL |
|
| March 2, 2023 |
NUTEX HEALTH Inc. reports fourth quarter and Full YEAR 2022 financial results NUTEX HEALTH Inc. reports fourth quarter and Full YEAR 2022 financial results ● Total revenue of $219.3 million for the year ended 2022 ● Net cash from operating activities of $50.6 million for the YEAR ended 2022 ● Company expects to open 19 NEW facilities by mid-2025 HOUSTON, TX − (PRNewswire) – MARCH 2, 2023 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 2, 2023 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| March 2, 2023 |
Supplemental Financial Disclosures Exhibit 99.2 Supplemental Financial Disclosures Revised Consolidated Balance Sheets June 30, 2022 As As Reported Revisions Revised Revised balance sheet information Total current assets $ 148,980,554 $ - $ 148,980,554 Goodwill 425,355,837 (10,331,537) 415,024,300 Other long-term assets 297,456,869 - 297,456,869 Total assets $ 871,793,260 $ (10,331,537) $ 861,461,723 Total liabilities $ 305,379,017 |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-41346 CUSIP Number: 67079U 108 (Check one): X Form 10-K Form 20-F Form 11-K Form 10-Q Form 10-D Form N-CEN Form N-CSR For Period Ended: December 31, 2022 Transition Report on Form 10-K Transition Report on Form 20-F Transition Report on F |
|
| February 28, 2023 |
Nutex Health Inc. Investor Presentation. Nutex Health Inc. Investor Presentation. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2023 NUTEX HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 28, 2023 |
Nutex Health Inc. Investor Presentation. S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A LC O N F I D E N T I A L 2 General The information contained in this Investor Presentation (“Presentation”) has been prepared by Nutex Health Inc. |
|
| January 12, 2023 |
S-3 Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) NUTEX HEALTH INC. |
|
| January 12, 2023 |
As filed with the Securities and Exchange Commission on January 11, 2023 As filed with the Securities and Exchange Commission on January 11, 2023 Registration No. |
|
| January 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2022 NUTEX HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| January 4, 2023 |
Partial Option Cancellation Agreement NUTEX HEALTH INC. PARTIAL OPTION CANCELLATION AGREEMENT This Stock Option Cancellation Agreement (this “Agreement”) is entered into as of December 29, 2022 (the “Cancellation Date”), by and between Warren Hosseinion (“Executive”) and Nutex Health Inc. (the “Company”), (each, a “Party” and collectively, the “Parties”). RECITALS WHEREAS, Clinigence Holdings, Inc (“Clinigence”), the predecessor to th |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2022 NUTEX HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 21, 2022 |
Nutex Health Inc. Investor Presentation. S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L S T R I C T L Y P R I V A T E A N D C O N F I D E N T I A L J. |
|
| December 21, 2022 |
NUTEX HEALTH to present at the 41st Annual J.P. Morgan Healthcare conference NUTEX HEALTH to present at the 41st Annual J.P. Morgan Healthcare conference HOUSTON, TX ? (PRNewswire) ? DECEMBER 21, 2022 ? Nutex Health Inc. (?Nutex Health? or the ?Company?) (NASDAQ: NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announ |
|
| December 21, 2022 |
Nutex Helath Presentation |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 22, 2022 |
NUTEX HEALTH reports THIRD quarter 2022 financial results and announces Common stock purchase agreement for a commitment to purchase up to $100 million worth of shares of its common stock with lincoln park capital • Net cash from operating activities of $46. |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53862 NUTEX |
|
| November 18, 2022 |
PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated effective as of November 14, 2022, is made by and between NUTEX HEALTH INC. |
|
| November 18, 2022 |
REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 14, 2022, is made by and between NUTEX HEALTH INC. |
|
| November 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2022 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 000-53862 CUSIP Number: 67079U 108 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: n/a Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 10, 2022 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 11, 2022 |
NUTEX HEALTH PROVIDES CORPORATE UPDATE NUTEX HEALTH PROVIDES CORPORATE UPDATE HOUSTON, TX ? (PRNewswire) ? October 10, 2022 ? Nutex Health Inc. |
|
| September 30, 2022 |
2019 Omnibus Equity Incentive Plan IGAMBIT, INC. 2019 OMNIBUS EQUITY INCENTIVE PLAN 1 IGAMBIT, INC. 2019 OMNIBUS EQUITY INCENTIVE PLAN TABLE OF CONTENTS SECTION 1. Establishment and Purpose. 3 (a) Purpose 3 (b) Adoption and Term 3 SECTION 2. Definitions. 3 SECTION 3. Administration. 6 (a) Committee of the Board of Directors 6 (b) Authority 6 (c) Exchange Program 6 (d) Delegation by the Committee 6 (e) Indemnification 6 SECTION 4. E |
|
| September 30, 2022 |
As filed with the Securities and Exchange Commission on September 30, 2022 As filed with the Securities and Exchange Commission on September 30, 2022 Registration No. |
|
| September 30, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) NUTEX HEALTH INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee(2) Equity Common Stock, $0.001 par v |
|
| September 30, 2022 |
S-3 Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) NUTEX HEALTH INC. |
|
| September 30, 2022 |
iGambit, Inc. 2006 Long-Term Incentive Plan iGambit Inc. 2006 LONG-TERM INCENTIVE PLAN AMENDED December 31, 2006 1. Definitions. In this Plan, except where the context otherwise indicates, the following definitions shall apply: 1.1. "Agreement" means a written agreement evidencing an Award. 1.2. "Award" means a grant of an Option, Right or Performance Award or an award of Restricted Shares or Incentive Shares. 1.3. "Board" means the Board o |
|
| September 30, 2022 |
Amended and Restated Nutex Health Inc. 2022 Equity Incentive Plan AMENDED AND RESTATED NUTEX HEALTH INC. 2022 EQUITY INCENTIVE PLAN 1 Table of Contents SECTION 1 Establishment and Purpose. 3 (a) Purpose 3 (b) Adoption and Term 3 SECTION 2 Definitions 3 SECTION 3 Administration 8 (a) Committee of the Board of Directors 8 (b) Authority 8 (c) Exchange Program 8 (d) Delegation by the Committee 9 (e) Indemnification 9 SECTION 4 Eligibility and Award Limitations 9 (a) |
|
| September 30, 2022 |
As filed with the Securities and Exchange Commission on September 30, 2022 As filed with the Securities and Exchange Commission on September 30, 2022 Registration No. |
|
| August 22, 2022 |
Commercial Lease Agreement For good and valuable consideration, the parties to this Commercial Lease Agreement (?Lease?) agree as follows: ARTICLE I DEFINED TERMS As used in this lease, the terms set forth in this Article One have the following meanings: 1. |
|
| August 22, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 22, 2022 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 22, 2022 |
(Ramping Hospitals) Contribution Agreement By And Among Nutex Health Holdco LLC, The Owners Listed on the Signature Pages Attached Hereto and The Owners? Representative November 23, 2021 i TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 1. |
|
| August 22, 2022 |
Amended and Restated Certificate of Incorporation of Clinigence Holdings, Inc. filed April 1, 2022 Delaware The First State Page 1 3211383 8100 Authentication: 203072436 SR# 20221270499 Date: 04-01-22 You may verify this certificate online at corp. |
|
| August 22, 2022 |
Exhibit 4.6 DESCRIPTION OF REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 DESCRIPTION OF CAPITAL STOCK The following description of the capital stock of Nutex Health Inc. (the ?Company? or ?we?) is based upon the Company?s amended and restated certificate of incorporation, the Company?s second amended and restated bylaws and applicable provisions o |
|
| August 22, 2022 |
REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of September 21, 2021, by and among Clinigence Holdings, Inc. |
|
| August 22, 2022 |
Amendment No. 1 dated as of July 1, 2022 to Registration Rights Agreement dated as of April 1, 2022 Exhibit 4.9 AMENDMENT TO REGISTRATION RIGHTS AGREEMENT This Amendment to REGISTRATION RIGHTS Agreement (this ?Amendment?) is entered into and made effective as of July 1, 2022 (?Effective Date?), by and among Nutex Health Inc., a Delaware corporation (the ?Company?) and Thomas T. Vo, in his capacity as the Nutex Representative (as defined below). Each of the foregoing may be referred to herein as |
|
| August 22, 2022 |
(Under Construction Hospitals) Contribution Agreement By And Among Nutex Health Holdco LLC, The Owners Listed on the Signature Pages Attached Hereto and The Owners? Representative November 23, 2021 i TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 1. |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-53862 NUTEX HEAL |
|
| August 22, 2022 |
EXHIBIT 10.12 CONSTRUCTION LOAN AGREEMENT THIS CONSTRUCTION LOAN AGREEMENT ("Loan Agreement"), dated as of ?, by and between ? ("Lender"), ? ("Borrower"), and THOMAS VO, M.D., an individual, ?* all having a partnership business address of 6030 S. Rice Ave., Ste. C, Houston, Texas 77081 (collectively, "Guarantor"). Preliminary Statement Borrower has applied to Lender for the Loan to aid Borrower in |
|
| August 22, 2022 |
Exhibit 21.1 NUTEX HEALTH INC. ? SUBSIDIARIES Company Jurisdiction of Organization Nutex Health Holdco LLC Delaware Tyvan LLC Texas Nutex Health LLC Texas Clinigence Health, Inc. Delaware AHP Health Management Services, Inc. Delaware Procare Health Inc. California Accountable Healthcare America, Inc. Delaware |
|
| August 22, 2022 |
Delaware The First State Page I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE RESTATED CERTIFICATE OF ?CLINIGENCE HOLDINGS, INC.?, CHANGING ITS NAME FROM "CLINIGENCE HOLDINGS, INC." TO "NUTEX HEALTH INC.", FILED IN THIS OFFICE ON THE FIRST DAY OF APRIL, A.D. 2022, AT 12:25 O`CLOCK P.M. 1 AMENDED AND RESTATED CERTI |
|
| August 22, 2022 |
NUTEX HEALTH reports secONd quarter 2022 financial results NUTEX HEALTH reports secONd quarter 2022 financial results ? EBITDA of $5.4 million for the second quarter of 2022 ? adjusted ebitda of $9.4 million for the second quarter of 2022 ? NET loss of $19.4 MILLION FOR THE SECOND QUARTER OF 2022 ? EBITDA of $29.7 million for the six months ended june 30, 2022 ? adjusted ebitda of $33.6 million for the six months ended june 30, 2022 ? NET INCOME OF $2.1 M |
|
| August 22, 2022 |
(Mature Hospitals) Contribution Agreement By And Among Nutex Health Holdco LLC, The Owners Listed on the Signature Pages Attached Hereto and The Owners? Representative November 23, 2021 i TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 1. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transition Report on Form N-SAR For the Transition Period Ended: n/a Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. |
|
| June 16, 2022 |
NUTEX HEALTH HOLDCO, LLC AND AFFILIATES COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND 2021 (UNAUDITED) 1 NUTEX HEALTH HOLDCO, LLC AND AFFILIATES TABLE OF CONTENTS Page COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS Combined and Consolidated Balance Sheets (Unaudited) 3 Combined and Consolidated Statements of Income (Unaudited) 4 Combined and Consolida |
|
| June 16, 2022 |
NUTEX HEALTH HOLDCO, LLC AND AFFILIATES COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS DECEMBER 31, 2021 AND 2020 (With Independent Registered Public Accounting Firm?s Report Thereon) 1 NUTEX HEALTH HOLDCO, LLC AND AFFILIATES TABLE OF CONTENTS Page REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM 3 COMBINED AND CONSOLIDATED FINANCIAL STATEMENTS Combined and Consolidated Balance Sheets 4 Com |
|
| June 16, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED PRO FORMA CONDENSED COMBINED CONSOLIDATED FINANCIAL STATEMENTS The unaudited pro forma condensed combined financial statements are presented to illustrate the estimated effects of the merger between Clinigence Holdings, Inc. |
|
| June 16, 2022 |
NUTEX HEALTH HOLDCO SUPPLEMENTAL INFORMATION NUTEX HEALTH HOLDCO SUPPLEMENTAL INFORMATION OVERVIEW Nutex Health Inc. (?Nutex Health? or the ?Company?), is a physician-led, technology-enabled healthcare services company comprised of its wholly owned subsidiary Nutex Health Holdco, LLC , with the 21 hospital facilities in eight states (hospital division), and a primary care-centric, risk-bearing population health management division. The hospi |
|
| June 16, 2022 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193 Date of Report (Date of earliest event reported): June 15, 2022 (April 1, 2022) NUTEX HEALTH INC. (formerly Clinigence Holdings, Inc.) (Exact name of registrant as specified in its charter) Delaware 000-53862 11-33 |
|
| June 10, 2022 |
Nutex health announces the appointment of jon bates as its new CHIEF FINANCIAL OFFICER EX-99.1 4 ex991.htm EXHIBIT 99.1 Nutex health announces the appointment of jon bates as its new CHIEF FINANCIAL OFFICER HOUSTON, TX − (PRNewswire) – June 10, 2022 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearin |
|
| June 10, 2022 |
Employment Agreement, dated as of June 8, 2022, between the Company and Jon Bates. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this ?Agreement?) is made and entered into as of June 8, 2022, by and between Nutex Health, Inc. |
|
| June 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 10, 2022 NUTEX HEALTH INC. (formerly Clinigence Holdings, Inc.) (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or Other Jurisdiction |
|
| June 10, 2022 |
Employment and Transition Agreement, dated as of June 8, 2022, between the Company and Michael Bowen EMPLOYMENT AND TRANSITION AGREEMENT This Employment and Transition Agreement (?Agreement?) is made as of June 8, 2022, by and between Michael Bowen (?Executive?) and Nutex Health Inc. |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended March 31, 2022. ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-53862 NUTEX HEALTH INC. (formerly known as Clinig |
|
| April 26, 2022 |
Form of Board of Directors Agreement BOARD OF DIRECTORS AGREEMENT This Board of Directors Agreement (?Agreement?) is made effective as April 20, 2022, by and between Nutex Health, Inc. |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 20, 2022 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| April 11, 2022 |
LOCK-UP AGREEMENT This Lock-Up Agreement (this “Agreement”) is entered into as of April 1, 2022 by and between the undersigned and Clinigence Holdings, Inc. |
|
| April 11, 2022 |
NUTX / Nutex Health Inc / Micro Hospital Holding LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Nutex Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67079U 108 (CUSIP Number) Micro Hospital Holding LLC Attn: Thomas D. Vo 6030 S. Rice Ave. Suite C Houston, TX 77081 (713) 357-2530 with a copy to: Gi |
|
| April 11, 2022 |
NUTEX HEALTH INC. REGISTRATION RIGHTS AGREEMENT NUTEX HEALTH INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of April 1, 2022 by and among Nutex Health Inc., a Delaware corporation (the “Company”), and the stockholders of Nutex Health Holdco LLC, a Delaware limited liability company (“Nutex”) set forth on Schedule A hereto (each a “Stockholder,” and collectively, the “Stockholders”). Unless ot |
|
| April 11, 2022 |
NUTEX HEALTH INC. REGISTRATION RIGHTS AGREEMENT NUTEX HEALTH INC. REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made as of April 1, 2022 by and among Nutex Health Inc., a Delaware corporation (the “Company”), and the stockholders of Nutex Health Holdco LLC, a Delaware limited liability company (“Nutex”) set forth on Schedule A hereto (each a “Stockholder,” and collectively, the “Stockholders”). Unless ot |
|
| April 11, 2022 |
NUTX / Nutex Health Inc / Premier Macy Management Holdings, LLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) Nutex Health Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67079U 108 (CUSIP Number) Premier Macy Management Holdings, LLC Attn: Matthew Stephen Young 2819 Cypress Dr. Texarkana, TX 75503 (903) 733-0257 with |
|
| April 11, 2022 |
LOCK-UP AGREEMENT This Lock-Up Agreement (this “Agreement”) is entered into as of April 1, 2022 by and between the undersigned and Clinigence Holdings, Inc. |
|
| April 4, 2022 |
Second Amended and Restated Bylaws Exhibit 3.2 SECOND AMENDED AND RESTATED BYLAWS OF NUTEX HEALTH INC. (formerly Clinigence Holdings, Inc.) Dated: April 1, 2022 ARTICLE I CORPORATE OFFICES 1.1 REGISTERED OFFICE The registered office of Nutex Health Inc. (the ?corporation?) shall be fixed in the corporation?s certificate of incorporation. References in these bylaws to the certificate of incorporation shall mean the certificate of in |
|
| April 4, 2022 |
Amended and Restated Certificate of Incorporation of Clinigence Holdings, Inc. filed April 1, 2022 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF CLINIGENCE HOLDINGS, INC. Clinigence Holdings, Inc., a corporation organized and existing under the General Corporation Law of the State of Delaware (the ?Corporation?) does hereby certify that: 1. The name of this Corporation is Clinigence Holdings, Inc. and this Corporation was originally incorporated pursuant to the General Corpor |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2022 NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 4, 2022 |
Amended and Restated Nutex Health Inc. 2022 Equity Incentive Plan AMENDED AND RESTATED NUTEX HEALTH INC. 2022 EQUITY INCENTIVE PLAN Table of Contents Page SECTION 1 Establishment and Purpose. 15 (a) Purpose.. 15 (b) Adoption and Term. .. 15 SECTION 2 Definitions. 15 SECTION 3 Administration. 19 (a) Committee of the Board of Directors. . 20 (b) Authority. 20 (c) Exchange Program.. 20 (d) Delegation by the Committee. 20 (e) Indemnification. . 21 SECTION 4 Eligibil |
|
| April 4, 2022 |
Execution Version Employment Agreement This Employment Agreement (the "Agreement") is made and entered into as of April 1, 2022, by and between Thomas T. |
|
| April 4, 2022 |
FORM OF EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") is made and entered into as of April 1, 2022, by and between Warren Hosseinion, M. |
|
| April 4, 2022 |
CLINIGENCE HOLDINGS and nutex health announce completion of merger and listing on the nasdaq capital market FT. |
|
| March 31, 2022 |
Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the accompanying Annual Report of Clinigence Holdings, Inc. (the ?Company?) on Form 10-K for the twelve months ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the ?Report?), I, Michael Bowen, Principa |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-53862 CLINIGENCE HOLDINGS, INC. (Exact name of registrant as spec |
|
| March 31, 2022 |
8-A12B 1 clnh033122form8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Clinigence Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 11-3363609 (State of incorporation or organization) (I.R.S. Employe |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) March 16, 2022 Clinigence Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or other jurisdiction of incorporation) (Commission |
|
| March 17, 2022 |
CLINIGENCE HOLDINGS ANNOUNCES RESULTS OF 2022 SPECIAL MEETING OF STOCKHOLDERS CLINIGENCE HOLDINGS ANNOUNCES RESULTS OF 2022 SPECIAL MEETING OF STOCKHOLDERS FT. LAUDERDALE, FL ? (PRNewswire) ? MARCH 16, 2022 ? Clinigence Holdings, Inc. (?Clinigence? or the ?Company?) (OTC:CLNH), a leading technology-enabled, risk-bearing population health management company, today announced results of votes taken at its Special Meeting of Stockholders held today . At the Special Meeting, the |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ?? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ?? Definitive Proxy Sta |
|
| February 3, 2022 |
Payment of Filing Fee (Check the appropriate box): EX-FILING FEES 6 exfiling.htm Payment of Filing Fee (Check the appropriate box): ☐ No fee required. ☒ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: Common Stock, par value $0.001 per share (2) Aggregate number of securities to which transaction applies: 587,357,079 shares of Common Stock (3) Per unit pri |
|
| February 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| December 15, 2021 |
PROCARE HEALTH, INC.. ACCOUNTANT'S COMPILATION REPORT AND FINANCIAL STATEMENTS September 30, 2021 EX-99.3 6 ex993.htm EXHIBIT 99.3 PROCARE HEALTH, INC.. ACCOUNTANT'S COMPILATION REPORT AND FINANCIAL STATEMENTS September 30, 2021 1 PROCARE HEALTH, INC. TABLE OF CONTENTS ACCOUNTANT'S COMPILATION REPORT 3 FINANCIAL STATEMENTS FOR THE NINE MONTH ENDED SEPTEMBER 30, 2021, 4 Balance Sheet 5 Statement of Income and Retained Earnings 6 Statement of Changes in Stockholders' equity 7 Statement of Cash F |
|
| December 15, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS EX-99.4 7 ex994.htm EXHIBIT 99.4 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS The accompanying unaudited pro forma condensed combined financial statements present the pro forma consolidated financial position and results of operations of the combined company based upon the historical financial statements of Clinigence Holdings, Inc. (Clinigence), and Procare Health, Inc. (Procare), |
|
| December 15, 2021 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) December 15, 2021 21 OCTOBER 2021 Clinigence Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or other jurisdiction of incor |
|
| December 15, 2021 |
PROCARE HEALTH, INC. INDEPENDENT AUDITOR'S REPORT AND FINANCIAL STATEMENTS December 31, 2020 EX-99.2 5 ex992.htm EXHIBIT 99.2 PROCARE HEALTH, INC. INDEPENDENT AUDITOR'S REPORT AND FINANCIAL STATEMENTS December 31, 2020 1 PROCARE HEALTH, INC. TABLE OF CONTENTS Page INDEPENDENT AUDITOR'S REPORT 3 FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2020 4 Balance Sheet 5 State of Income Retained Earnings 6 Statement of Changes in Stockholders' equity 7 Statement of Cash Flows 8 NOTES TO FIN |
|
| November 24, 2021 |
AGREEMENT AND PLAN OF MERGER BY AND AMONG NUTEX HEALTH HOLDCO LLC, CLINIGENCE HOLDINGS, INC. |
|
| November 24, 2021 |
CLINIGENCE HOLDINGS and nutex health announce transformational merger CLINIGENCE HOLDINGS and nutex health announce transformational merger FT. LAUDERDALE, FL and HOUSTON, TX ? (PRNewswire) ? November 24, 2021 ? Clinigence Holdings, Inc. (?Clinigence? or the ?Company?) (OTC:CLNH), a leading technology-enabled, risk-bearing population health management company, and Nutex Health, LLC (together with its affiliates, ?Nutex?), one of the largest independent operators of |
|
| November 24, 2021 |
AMENDMENT TO EMPLOYMENT AGREEMENT EX-99.2 6 ex992.htm EXHIBIT 99.2 AMENDMENT TO EMPLOYMENT AGREEMENT WHEREAS, the Board of Directors of Clinigence Holdings, Inc. (the “Company”) has approved that a Gross-Up Payment (as defined below) be payable to the extent that an Excise Tax (as defined below) is or becomes assessable against Warren Hosseinion (the “Employee”) because any payments received by the Employee in connection with the |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) November 22, 2021 Clinigence Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or other jurisdiction of incorporation) (Commiss |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended September 30, 2021. ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-53862 Clinigence Holdings, Inc. (Exact name o |
|
| October 21, 2021 |
EX-2.1 2 ex21.htm EXHIBIT 2.1 AGREEMENT AND PLAN OF MERGER This Agreement and Plan of Merger (“Agreement”) is dated and effective as of October 1, 2021 (the “Effective Date”), by and by and between Clinigence Holdings, Inc., a Delaware corporation (“Parent”), Clinigence Procare Health Inc, a Delaware corporation (“Merger Sub”), Procare Health, Inc., a California corporation (“Company”), Anh Nguyen |
|
| October 21, 2021 |
CLINIGENCE HOLDINGS announces the acquisition of procare health FT. LAUDERDALE, FL ? (PRNewswire) ? October 21, 2021 ? Clinigence Holdings, Inc. (?Clinigence? or the ?Company?) (OTC: CLNH), one of the nation?s leading technology-enabled, risk-bearing population health management companies, today announced that it has completed the acquisition of ProCare Health, Inc. (?ProCare?). Based in Garden Gr |
|
| October 21, 2021 |
Employment and Restrictive Covenant Agreement with Anh Nguyen. EX-2.2 3 ex22.htm EXHIBIT 2.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into as of October 1, 2021 by and between Procare Health, Inc., a California corporation (the “Company”), and Anh Nguyen (the “Employee” and together with the Company referred to as the “Parties”) to become effective as of the date hereof (the “Effective Date”). For good and valuable |
|
| October 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 21, 2021 Clinigence Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or other jurisdiction of incorporation) (Commissi |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 1, 2021 Clinigence Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or other jurisdiction of incorporation) (Commissio |
|
| October 1, 2021 |
EX-3.02 2 ex302.htm SECURITIES PURCHASE AGREEMENT Clinigence Holdings, Inc. (Seller) and Apollo Medical Holdings, Inc., a Delaware corporation or its designated Affiliate (Purchaser) 1 TABLE OF CONTENTS Article I. 1 1.1 Definitions 1 Article II. 3 2.1 Closing; Exchange 3 2.2 Deliveries 3 2.3 Closing Conditions 4 Article III. 5 3.1 Representations and Warranties of the Company 5 3.2 Representations |
|
| October 1, 2021 |
EX-99.1 3 ex991.htm EXHIBIT 99.1 September 23, 2021 Clinigence Holdings Announces the Completion of a $3 Million Strategic Equity Investment from ApolloMed FT. LAUDERDALE, Fla. and ALHAMBRA, Calif., Sept. 23, 2021 /PRNewswire/ - Clinigence Holdings, Inc. ("Clinigence") (OTC: CLNH), one of the nation's leading technology-enabled, risk-bearing population health management companies, today announced |
|
| August 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly period ended June 30, 2021. ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from to Commission file number 000-53862 Clinigence Holdings, Inc. (Exact name of sma |
|
| July 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 22, 2021 Clinigence Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 000-53862 11-3363609 (State or other jurisdiction of incorporation) (Commission |
|
| May 25, 2021 |
CLNH / Clinigence Holdings Inc / Dominis-Embree AHA Investor, LLC - SC 13G Passive Investment SC 13G 1 clnh052421formsch13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) * CLINIGENCE HOLDINGS, INC. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 18727D105 (CUSIP Number) February 26, 2021 (Date of Event Which Requires Filing of This Statement) |
